Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02621931 · ClinicalTrials.gov registry record · Phase 3
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,130
- Enrollment target
NCT02621931 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,130 participants.
The verdict
NCT02621931, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,130 participants
- Enrollment target
Study Summary
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
Interventions
- DRUG Placebo
- DRUG Fremanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,130 participants |
| Start Date | 2016-03-22 |
| Est. Completion | 2017-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02621931
The ClinicalTrials.gov registry entry for NCT02621931 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02621931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02621931 about?
NCT02621931 is a clinical study titled "Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine". The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
What is the current status of trial NCT02621931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,130 participants. The study started on 2016-03-22. Estimated completion is 2017-04-11.
What interventions are being tested in trial NCT02621931?
The interventions under investigation include: Placebo (DRUG), Fremanezumab (DRUG).
Who is sponsoring clinical trial NCT02621931?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.